About MITRO

Evolution

2023

MITRO completed the construction of radioactive pathology platform MITRO completed the first GMP production of radiopharmaceuticals MITRO won the title of Jiangsu private science and technology enterprise MITRO completed the acquisition of Xing Imaging LLC MITRO was honored as Jiangsu Province's postgraduate workstation MITRO won the honorary title of specialized, fined, special, new small and medium-sized enterprise in Jiangsu province in 2023 MITRO's first full-service CRDMO project got clinical approval from NMPA (China FDA)

2024

MITRO completed Series A financing of nearly 400 million yuan Mr. Haowei Wu, the General Manager of MITRO, became the Industry Professor in Nanjing Medical University in 2024 MITRO had the honor to get the " Gazelle Enterprise” in Jiangsu Province in 2024 MITRO officially opened the FIH (First in Human, FIH) center in United States

2012

MITRO Biotech. Co., Ltd. was founded

2013

The first 89Zr labeling trial

2014

MITRO Nanjing Laboratory Phase I was completed MITRO first microPET was installed

2015

MITRO obtained the license to use laboratory animals MITRO performed the first 89Zr-PD-L1 study project MITRO performed the first Phase 0 clinical study of molecular imaging MITRO performed the first nuclide labeled stem cells project

2016

MITRO performed the first nuclide-labeled ADC project MITRO received on-site verification by NMPA (China FDA) for the first time and passed MITRO Nanjing Laboratory phase II passed radiation environmental assessment MITRO was recognized as a National High-Tech Enterprise

2017

MITRO completed the first study on the localization of original research and development of radiopharmaceuticals MITRO successfully applied for the National 13th Five-Year Project

2018

MITRO’s first clinical PET-CT installation allows large animal scanning MITRO Nanjing Laboratory Phase II was completed MITRO was successfully accredited by the international animal welfare AAALAC

2019

MITRO Nanjing Laboratory Phase II officially opened

2020

MITRO Clinical was founded MITRO performed the first clinical phase III study of 18F drug MITRO performed the first in vivo quantitative PK study on polysaccharides Mido successfully achieved 89Zr-labeled CAR-T cells

2021

MITRO’s collaborative project won the second prize of Jiangsu Science and Technology Award MITRO and Nanjing Medical University established the Joint Innovation Center of Excellence in Molecular Imaging and Novel Drug Development

2022

MITRO was accredited as Nanjing Engineering Technology Research Center MITRO was listed as a Gazelle enterprise of the 2022 Jiangsu High-Tech Zone MITRO validates MPTP unilaterally induced Parkinson's disease model in cynomolgus monkeys by PET technology MITRO successfully labeled exosomes with 89Zr MITRO passed the National Intellectual Property Management System certification for the first time

Qualifications and Honors